National Cancer Institute (PDQ Adult Treatment Editorial Board), 2025-02-12: NCI's PDQ summary states that the value of adjuvant chemotherapy in stage II colon cancer remains controversial, notes a 2% to 4% overall-survival improvement in pooled analyses of 5-FU-based therapy, and says adjuvant therapy is not indicated for most stage II patients outside a trial.
The decision to use adjuvant chemotherapy for patients with stage II colon cancer is complicated and requires thoughtful consideration by both patients and their physicians. Adjuvant therapy is not indicated for most patients unless they are entered into a clinical trial.
Treatment of Stage II Colon Cancer > Adjuvant chemotherapy
National Cancer Institute (PDQ Adult Treatment Editorial Board), 2025-02-12: NCI's PDQ summary states that the value of adjuvant chemotherapy in stage II colon cancer remains controversial, notes a 2% to 4% overall-survival improvement in pooled analyses of 5-FU-based therapy, and says adjuvant therapy is not indicated for most stage II patients outside a trial. US federal document. PDQ pages are revised continuously; date shown is 'Updated: February 12, 2025' as displayed at retrieval on 2026-11-18. No funder/COI (government). Also records a meta-analysis mortality risk ratio of 0.87 (95% CI 0.75-1.01; P=.07) for stage II. No PDF version – HTML only. Study type: review.
